Omeros Corporation Secures $22 Million in Strategic Direct Offering

Omeros Corporation (NASDAQ: OMER) has successfully raised approximately $22 million through a registered direct offering, with D. Boral Capital LLC serving as the exclusive placement agent. The transaction, finalized on July 28, 2025, involved the sale of 5,365,853 shares of common stock at $4.10 per share, representing a 14% premium over the closing price on July 24, 2025. This strategic move was executed under a 'shelf' Registration Statement on Form S-3 (File No. 333-268269), demonstrating Omeros Corporation's proactive approach to securing funding for its biopharmaceutical endeavors.

The participation of Polar Asset Management Partners as a significant investor in this offering reflects a strong vote of confidence in Omeros Corporation's potential and the broader biopharmaceutical sector. This capital infusion is poised to accelerate the company's research and development initiatives, underscoring the critical role of financial strategies in overcoming the hurdles of drug development and commercialization.

D. Boral Capital LLC's role in this transaction underscores its expertise in facilitating complex financial deals for middle-market and emerging growth companies. With a history of aggregating around $30 billion in capital since its establishment in 2020, the firm has solidified its reputation as a leading investment bank. For more details on D. Boral Capital LLC's services and achievements, visit https://dboralcapital.com/.

This offering not only provides Omeros Corporation with essential funding but also signals increasing investor interest in the biopharmaceutical industry. It exemplifies how companies are leveraging financial ingenuity to navigate the competitive landscape of drug development, marking a significant step forward in Omeros Corporation's growth trajectory.